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Strengths and limitations of this study
 ► To the best of our knowledge, this will be the first 
systematic review assessing the association be-
tween common clinically symptomatic bacterial 
infections and the risk of incident cognitive decline 
and dementia in longitudinal studies.
 ► We will perform a comprehensive search of pub-
lished and grey literature with no restrictions on 
date, language or geographical location.
 ► The review will develop existing evidence to gen-
erate better knowledge on the magnitude and 
direction of the relationship between common bac-
terial infections and subsequent cognitive decline or 
dementia.
 ► Heterogeneity in the way infections, cognitive de-
cline and dementia are defined is expected, which 
could affect the feasibility of performing a me-
ta-analysis and interpretation of findings.
 ► There may be difficulty ascertaining whether lower 
respiratory tract infections are bacterial or viral.
ABSTRACT
Introduction The global burden of dementia is rising, 
emphasising the urgent need to develop effective 
approaches to risk reduction. Recent evidence suggests 
that common bacterial infections may increase the risk 
of dementia, however the magnitude and timing of the 
association as well as the patient groups affected remains 
unclear. We will review existing evidence of the association 
between common bacterial infections and incident 
cognitive decline or dementia.
Methods and analysis We will conduct a comprehensive 
search of published and grey literature from inception to 
18 March 2019. The following electronic databases will 
be searched; MEDLINE, EMBASE, Global health, PsycINFO, 
Web of Science, Scopus, Cochrane Library, the Cumulative 
Index to Nursing and Allied Health Literature, Open Grey 
and the British Library of Electronic Theses databases. 
There will be no restrictions on the date, language or 
geographical location of the studies. We will include 
longitudinal studies with a common clinically symptomatic 
bacterial infection as an exposure and incident cognitive 
decline or dementia as an outcome. Study selection, data 
extraction and risk of bias will be performed independently 
by two researchers. We will assess the risk of bias 
using the Cochrane collaboration approach. The overall 
quality of the studies will be assessed using the Grading 
of Recommendations, Assessment, Development and 
Evaluations criteria. We will explore the heterogeneity of 
relevant studies and, if feasible, a meta-analysis will be 
performed, otherwise we will present a narrative synthesis. 
We will group the results by exposure and outcome 
definitions and differences will be described by subgroups 
and outcomes.
Ethics and dissemination Ethical approval will not be 
required as this is a systematic review of existing research 
in the public domain. Results will be disseminated in 
a peer-reviewed journal and presented at national and 
international meetings and conferences.
PROSPERO registration number CRD42018119294.
InTROduCTIOn
Rationale
Dementia is a clinical syndrome that signifi-
cantly contributes to disability and depen-
dence worldwide, with a devastating impact 
on individuals, caregivers and healthcare 
services.1–3 It is characterised by a progressive 
deterioration in cognition and behaviour 
that interferes with an individual’s ability to 
perform activities of daily living.4 In 2018, 
approximately 50 million people worldwide 
were estimated to be living with dementia, and 
this figure is projected to rise to 152 million 
by 2050.5
Age is the single biggest risk factor for 
dementia, with the risk doubling every 5 
years after the age of 65.6 Despite this, there 
have been some indications that the risk for 
dementia can be reduced, with more recent 
cohorts in the UK demonstrating a signifi-
cantly lower risk at any given age.7 It has 
become clear from clinical and neuropatho-
logical studies that the risk for dementia is 
complex, not driven by genetics, vascular 
factors or age alone. Given the rapidly 
increasing ageing population and the absence 
of pharmacological treatments that can delay 
the onset or progression of dementia, identi-
fication of effective strategies to reduce risk, 
as age increases, has become a public health 
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priority.8 As a result, recent literature has focused on 
modifiable risk factors. It has been estimated that around 
a third of dementia cases worldwide can be attributed to 
modifiable risk factors.9–11
Bacterial infections have been identified as potential 
risk factors for dementia. For the past few decades, a 
large body of research has been published on the asso-
ciation between bacterial pathogens and Alzheimer’s 
disease, particularly in postmortem brain tissue.12–14 
Despite this, the temporality of this relationship remains 
unclear due to the cross-sectional nature of the data 
collected in these studies. A recent meta-analysis of 27 
serological, cerebrospinal fluid and postmortem brain 
studies found that infections due to Chlamydia pneu-
moniae and Spirochaetes were associated with a 5-fold 
(OR 5.66; 95% CI 1.83 to 17.51) and 10-fold (OR 10.61; 
95% CI 3.38 to 33.29) increased risk of Alzheimer’s 
disease, respectively.15 However, temporality could not be 
assessed in these studies. The meta-analysis was further 
limited by the inclusion of studies with small sample sizes 
and the focus on Alzheimer’s disease rather than all types 
of dementia.
Common bacterial infections are well recognised to be 
associated with acute changes in cognition, manifested 
as delirium, among older adults.16 In turn, delirium is 
strongly associated with an increased risk of subsequent 
cognitive decline and dementia.17–19 This raises the chal-
lenge of disentangling the relative contribution of the 
(potentially reversible) ageing immune system’s response 
to acute infections, from ongoing neuropathological 
processes, both of which may affect cognition.
Longitudinal studies with a follow-up time sufficient 
enough for delirium to resolve, are important in distin-
guishing between delirium and long-term cognitive 
impairment. Additionally, longitudinal studies that 
compare incidence of cognitive decline or dementia in 
individuals with and without common bacterial infections 
provide evidence for the temporality and magnitude of 
this association. Although the prevalence of common 
bacterial infections, such as pneumonia and urinary tract 
infections, in individuals with dementia is well known,20 21 
the incidence of cognitive decline and dementia is less 
established.
The mechanisms by which bacterial infections may 
increase the risk of cognitive decline and dementia are 
unclear but may involve inflammation.22 23 Bacterial infec-
tions may trigger an inflammatory response in the brain 
resulting in the release of pro-inflammatory mediators 
and activation of cytotoxic microglia. This may result in 
deterioration of cognitive function, possibly increasing 
the risk of dementia.12
To date, no systematic review has been performed on 
the incidence of cognitive decline and dementia in indi-
viduals with a common bacterial infection causing clin-
ical illness. As these infections frequently occur in the 
community, early recognition, treatment or prevention of 
common bacterial infections could have important public 
health implications in reducing the burden of dementia.
Objectives
The primary objective of the proposed systematic review 
is to summarise the current literature investigating the 
association between common clinically symptomatic 
bacterial infections (sepsis, lower respiratory tract infec-
tions, urinary tract infections and skin and soft tissue 
infections) and incident cognitive decline and dementia 
in longitudinal studies. A secondary objective will be 
to identify gaps in literature and recommendations for 
future research on this topic.
METhOdS
The present systematic review protocol was developed 
according to the Preferred Reporting Items for System-
atic Reviews and Meta-analyses Protocols (PRISMA-P) 
statement and was registered on the PROSPERO data-
base.24 25 Any amendments to the protocol will be updated 
in PROSPERO.
We will report the systematic review in line with the 
PRISMA statement.26 If a meta-analysis is feasible, it will 
be reported according to the Meta-analysis of Observa-
tional Studies in Epidemiology statement.27
Eligibility criteria
Studies will be eligible for inclusion into the present study 
if they meet the inclusion criteria mentioned below.
Study design
We will include longitudinal studies; retrospective and 
prospective cohort studies, case-control studies and 
randomised controlled trials (RCTs). We will include 
studies specifically investigating the association between 
common bacterial infections and cognitive decline or 
dementia. Although it would not be possible to perform 
RCTs specifically addressing our research question, we 
will consider studies derived from RCTs which could 
include cohort or case-control studies from an RCT data 
source. We will include studies in which the exposure 
is ascertained prior to the occurrence of the outcome 
events in order to investigate the temporal relationship 
between common bacterial infections and subsequent 
cognitive decline or dementia. Additionally, to avoid 
including studies focusing on short-term reversible 
changes in cognition, rather than long-term cognitive 
decline, we will include studies in which cognitive decline 
was measured at least 3 months following infection.
Study population
We will include human studies of adults aged 18 years and 
over with no restrictions on the sex, ethnicity, prior health 
status or residence of participants. We will include studies 
conducted in any healthcare setting.
Exposure
We will include studies in which exposure is defined as 
symptomatic illness due to common bacterial infections, 
either suspected clinically or confirmed by isolation of a 
bacterial pathogen. Types of bacterial infections will be 
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subdivided into sepsis, lower respiratory tract infections, 
skin and soft tissue infections and urinary tract infections. 
The possible pathophysiological mechanisms of bacterial 
infections on cognitive decline or dementia may differ 
depending on the site of infection, and thus we will only 
include studies assessing the independent effect of each 
type of infection on our outcomes. In addition, infections 
are likely to differ in terms of severity, particularly sepsis, 
which further highlights the need to assess their effect 
separately. We will exclude studies that focus on a specific 
bacterial pathogen as the exposure rather than the symp-
tomatic disease (ie, isolation of a bacterium by PCR alone 
in the absence of clinical symptoms).
Comparators
Studies eligible for inclusion will include a comparison 
group. For cohort studies and secondary analyses of 
longitudinal RCT data, individuals exposed to common 
bacterial infections will be compared with those unex-
posed to infections. For case-control studies, cases with 
dementia or cognitive decline will be compared with a 
control group without dementia or cognitive decline.
Outcomes
We will have two primary outcomes. These will be (1) 
incident cognitive decline and (2) incident dementia 
(all types). Cognitive decline will be defined clinically. 
Dementia will also be defined clinically, with or without 
neuroimaging or histopathology. If a sufficient number of 
eligible studies are available, dementia will be subdivided 
into dementia types.
Literature searches
We will systematically search electronic databases of 
published and grey literature from inception to 18 
March 2019. The following databases will be searched: 
MEDLINE (Ovid interface), EMBASE (Ovid interface), 
Global health (Ovid interface), PsycINFO (Ovid Inter-
face), Web of Science, Scopus, Cochrane Library, the 
Cumulative Index to Nursing and Allied Health Liter-
ature, Open Grey and the British Library of Electronic 
Theses databases. Additionally, we will search the refer-
ence lists of the included studies to identify any relevant 
articles not captured in the search strategy. We will search 
the databases using subject headings, where possible, 
and keywords related to the exposure, outcome and 
study design. These search terms will be combined using 
Boolean logical operators.
We carried out a preliminary search on PubMed to 
ensure we would capture a sufficient number of studies 
for inclusion into the review. We developed a search 
strategy for the MEDLINE database which is provided in 
online supplementary appendix 1. The search strategy 
was developed in consultation with a librarian at the 
London School of Hygiene and Tropical Medicine and 
was subsequently peer reviewed based on the Peer-Re-
view for Electronic Search Strategies.28 We will translate 
our search strategy in all databases using search syntaxes 
specific to each database. No restrictions will be placed 
on the geographical location, language or date of publi-
cation of the studies. Any potentially relevant non-English 
studies will be translated.
Study records
Data management
We will import the search results into the reference 
manager software EndNote (X8.0.2). Duplicate entries 
will be identified and removed.
Study selection
Two researchers will independently screen all titles and 
abstracts against the eligibility criteria. The researchers 
will then independently screen the full-text articles of 
potentially eligible articles and decide on whether the 
inclusion criteria have been met. Any disagreements 
between the reviewers will be discussed and if necessary 
a third reviewer will be consulted. Reasons for exclusion 
of studies will be recorded. We will document the study 
selection process using the PRISMA flow diagram.26 If 
multiple papers arise from the same population, we will 
include the paper with the largest sample size and most 
detailed information about the exposure and outcome. 
We pilot tested our study selection process to ensure that 
the inclusion criteria can be reliably applied.
Data collection process
Two researchers will independently extract data from 
included papers onto a predesigned form. If necessary, 
the authors will be contacted directly to obtain any 
missing information. We will perform pilot testing on the 
data extraction form to identify any missing or irrelevant 
criteria, and we will modify the form accordingly.
data items
We will use the Population, Exposure, Comparator, 
Outcomes and Study characteristics framework to design 
our data extraction form. The following information will 
be extracted:
1. Population: age (mean, median or range), sex, inclu-
sion and exclusion criteria.
2. Exposure: definition of exposure, type of bacterial in-
fection, cause of sepsis, number of exposed.
3. Comparators: identification and definition of compar-
ator, number of comparators.
4. Outcomes: definition of outcome and identification 
of cognitive decline and dementia, number of partici-
pants with the outcome.
5. Study characteristics: authors, name of study, year of 
publication, study design, type of longitudinal study, 
healthcare setting, country, sample size, duration of 
follow-up.
Regarding the study results, we will extract unadjusted 
and adjusted estimates and their corresponding 95% CI 
for each exposure and outcome. Data on subgroup or 
sensitivity analyses will be extracted. We will extract addi-
tional data on antibiotic treatment, if indicated, given 
that antibiotics have been associated with delirium,29 
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which is in turn a risk factor for cognitive decline and 
dementia. We will also extract data on confounding vari-
ables. Factors considered to be potential confounders 
include age,30 sex,31 socioeconomic status,32 ethnicity,33 
smoking,34 alcohol consumption,35 cardiovascular 
disease,36 diabetes,37 renal dysfunction,38 psychiatric 
disorders,39 cerebrovascular disease,40 chronic obstructive 
pulmonary disease41 and immunodeficiency disorders.42 
We will assess whether studies have adequately assessed 
for potential confounders as part of our risk of bias and 
study quality assessments.
Risk of bias in individual studies
We will use a sample of studies to pilot test the risk of bias 
form to ensure the criteria can be applied consistently 
by both reviewers. Two researchers will independently 
assess the risk of bias in line with the Cochrane collabo-
ration approach.43 44 We will examine the risk of bias for 
RCTs using the following domains: sequence generation; 
allocation concealment; blinding of participants and 
personnel; blinding of outcome assessment; incomplete 
outcome data; selective outcome reporting and other 
potential threats to validity.44 We will assess the risk of bias 
for observational studies using the following domains: 
confounding, selection of participants, misclassification 
of variables, missing data, reverse causation, generalis-
ability and study power.
data synthesis and meta-bias(es)
We will group studies according to the outcome (cogni-
tive decline or dementia) and exposure (type of common 
bacterial infection) and synthesise them narratively. Data 
will be summarised in predefined tables. We will consider 
subgroup analyses according to age group, gender, 
dementia subtype and risk of bias. If possible, we will 
explore the effect of antibiotic treatment on cognitive 
decline or dementia.
A meta-analysis will be considered feasible if there are a 
minimum of at least two studies that are homogeneous in 
terms of study design, type of common bacterial infection 
and type of outcome. We will pool effect measures (ORs, 
risk ratios or HRs) from the studies in order to perform 
the meta-analysis.
We will assess statistical heterogeneity through the use 
of forest plot, χ2 test and I2 statistic. Depending on the 
level of heterogeneity, a fixed or random effects model 
will be selected to calculate the pooled incidence and 
corresponding 95% CI. A χ2 test with a p value of 0.1 will 
be considered statistically significant. We will consider 
an I2 value of >25% to indicate moderate heterogeneity, 
which will guide the use of a random effects model.45 46 We 
will assess publication bias and small study effects using 
funnel plots, provided that there are 10 or more studies 
eligible for inclusion into the meta-analysis.47
Confidence in cumulative evidence
We will assess the overall quality of evidence for each 
outcome using the Grading of Recommendations, 
Assessment, Development and Evaluation tool.48 The 
domains assessed will include study limitations, inconsis-
tency, indirectness, imprecision and publication bias.49 
The strength of the evidence will be categorised as high, 
moderate, low and very low.
Patient and public involvement
No patients or public were directly involved in the design 
of this study. However, we sought advice on the dissem-
ination of our findings from lay volunteers assigned to 
Rutendo Muzambi’s PhD studentship by the Alzheimer’s 
Society.
EThICS And dISSEMInATIOn
This systematic review will provide evidence for the role 
of common bacterial infections in the development of 
cognitive decline and dementia. The systematic review 
will be submitted for publication in a peer-reviewed 
journal and the results may be presented at national and 
international conferences and meetings relevant to the 
field. This review will highlight gaps in current literature 
and identify future research directions.
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